Skip to main content
Equibles
GCTK logo

GCTK · Glucotrack, Inc. · Metrics

Track GCTK — free

Use GCTK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GCTK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.15 +0.04 (+3.57%) At close · Oct 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based upon this review and our current financial condition, we have concluded that substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.28M
Shares
705,255
Volume · Oct 6 176.04K Avg daily vol (25 sessions) 3.46M

GCTK metrics

44 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.11
Market cap
$1.28M

Price action

20 metrics
Price change (1W)
-38.3%
Price change (30D)
-62.1%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
19.2
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
3.46M
Relative volume
0.1
Average dollar volume
$8.14M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
705,255

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
18.3×
reciprocal yield 5.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,242.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
1,685.6%
Trailing 12 months
Net margin
1,690.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$15.40M
Net income (TTM)
−$15.95M
Trailing 12 months
Diluted EPS (TTM)
$-226.95
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$46.58

Growth

11 metrics
Revenue growth YoY
-99.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$70,016
Trailing 12 months
EPS growth YoY
-92.1%
Shares change YoY
+913.0%
Year over year · more shares
Revenue CAGR (3Y)
-30.2%
Revenue CAGR (5Y)
+28.3%
EPS CAGR (3Y)
-73.8%
EPS CAGR (5Y)
-51.3%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1,066.7%
Debt / equity
—
Current ratio
0.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.12M
Latest balance sheet
Cash & equivalents
$1.12M
Total assets
$1.50M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$16.22M
Capital expenditures (TTM)
$96,000
R&D (TTM)
$8.94M
SG&A (TTM)
$1.32M
Stock compensation (TTM)
$251,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
19
13F filer change QoQ
+6
Institutional ownership
5.6%

Short interest

3 metrics
Short interest
13.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1506983 CUSIP 45824Q804 Visit website Investor relations